Press Releases for SEPR

Press Releases
Dainippon Sumitomo Pharma Co., Ltd. Completes Acquisition of Sepracor Inc.
Jefferies Expands International Healthcare Investment Banking Platform
Sepracor Announces Expiration of Hart-Scott-Rodino Waiting Period
Levi &Amp; Korsinsky, LLP Announces Class Action Lawsuit Against Sepracor, Inc. -- SEPR
Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Sepracor, Inc.
Dainippon Sumitomo Pharma to Acquire Sepracor for U.S. $23.00 Per Share in an All-Cash Tender Offer Valued at Approximately U.S. $2.6 Billion
BenchmarkJournal.Com Free Analyst Review for ESRX, PDCO, FMCN, SEPR, PETM and CTSH
Sepracor Announces New Drug Submission (NDS) to Health Canada for STEDESA™ as Adjunctive Treatment for Epilepsy
Sepracor Inc. Reports Strong Second Quarter 2009 Operating Results and Increases Financial Guidance for 2009
Sepracor Inc. Sets Conference Call and Webcast for Second Quarter 2009 Operating Results
Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA® Pediatrics
CombinatoRx and Neuromed Sign Merger Agreement
Sepracor’s STEDESA™ (Eslicarbazepine Acetate) New Drug Application Formally Accepted for Review by the FDA
Sepracor Reports Strong First Quarter 2009 Operating Results and Reiterates Financial Guidance for 2009
Sepracor Reports Preliminary Phase III Study Results for OMNARIS® HFA Nasal Aerosol in Seasonal Allergic Rhinitis
Sepracor Inc. Sets Conference Call and Webcast for First Quarter 2009 Operating Results
MaybachFinancial.Com Posts Free Analyst Report on INSM, SEPR, UAUA and OFIX
Sepracor Announces Patent Interference Proceedings (and Schedule) Against Wyeth for Claims Related to O-Desmethylvenlafaxine Succinate (Marketed As PRISTIQ®)
Sepracor Announces Patent Interference Proceedings (and Schedule) Against Wyeth for Claims Related to O-desmethylvenlafaxine Succinate (Marketed as PRISTIQ®)
Sepracor Announces Submission of STEDESA(™) New Drug Application to FDA for Adjunctive Treatment of Epilepsy
Sepracor Files Patent Infringement Lawsuit Against Eszopiclone ANDA Filers
Sepracor Completes Tender Offer for 0% Convertible Senior Subordinated Notes Due 2024
Quarterly Changes to the NASDAQ Q-50 Index
Sepracor Announces Final Settlement of XOPENEX® Inhalation Solution Patent Infringement Litigation With Barr Laboratories, Inc. And Grant of Non-Exclusive License to Barr and Teva Pharmaceuticals USA, Inc.
Sepracor Announces Final Settlement of XOPENEX® Inhalation Solution Patent Infringement Litigation with Barr Laboratories, Inc. and Grant of Non-Exclusive License to Barr and Teva Pharmaceuticals USA, Inc.
Sepracor Reports Preliminary Phase II Study Results for SEP-225441 for the Treatment of Generalized Anxiety Disorder
Zacks Releases New Stock Picks From the +21.7% Value Strategy: Sepracor, Health Net, United Western Bancorp, Plains Exploration & Production Co. And Carrols Restaurant Group
Sepracor Announces Tender Offer for 0% Convertible Senior Subordinated Notes Due 2024
Zacks Upgrades and Revisions Strategy Highlights: UFP Technologies, Nuance Communications, NetScout Systems and Sepracor
Wall Street News Alert: Hot Stocks to Watch: SOIS! January 30, 2009
Sepracor Announces Strategic Corporate Restructuring and Workforce Reduction Plan in Addition to 2009 Financial Guidance
Sepracor Reports Fourth Quarter and Full-Year 2008 Operating Results
Sepracor Inc. Sets Conference Call and Webcast for Fourth Quarter and Full-Year 2008 Operating Results
Zacks Analyst Blog Highlights: Apple Inc., Investors Real Estate Trust, Sepracor, Inc., Moody's Corporation and Satyam Computer Services Ltd.
Zacks Bull and Bear of the Day Highlights: EnCana, UST, Investors Real Estate Trust, Sepracor and Moody's
Results of Studies of Eslicarbazepine Acetate for the Treatment of Epilepsy to Be Presented at American Epilepsy Society Annual Meeting
Results of Studies of ALVESCO(R) for the Treatment of Asthma and OMNARIS(TM) in an HFA Nasal Aerosol Presented at American College of Allergy, Asthma & Immunology Annual Meeting
Sepracor Inc. Reports 9.6% Increase in Revenue for Third Quarter and Tightens Range for Full-Year 2008 Financial Guidance
European Medicines Agency (EMEA) Issues Positive Opinion For LUNIVIA(R) (Eszopiclone) Marketing Authorization Application (MAA) In Europe
Sepracor Inc. Sets Conference Call and Webcast for Third Quarter Operating Results
New Data Show Efficacy and Safety of Eslicarbazepine Acetate in the Treatment of Epilepsy
Zacks Bull and Bear of the Day Highlights: The Medicines Company, Hibbett Sports, Sepracor, Johnson Controls and ASM International - Sep 11 2008 11:14AM
ALVESCO(R) (Ciclesonide) Inhalation Aerosol Now Available in U.S. for Treatment of Asthma
LUNESTA(R) Next-Day Function and Discontinuation Data from a Long-Term 12-Week Study in Elderly Patients Presented at ECNP
Sepracor Announces Senior Management Appointments
Sepracor Inc. Reports Second Quarter 2008 Results
Sepracor Inc. Sets Conference Call and Webcast for Second Quarter Operating Results
Sepracor Announces Full Support of PhRMA's Revised Code on Interactions with Healthcare Professionals
Sepracor Inc. Presented Leadership Award for Contributions to Growth of Community
Sepracor Announces Phase III Data for Eslicarbazepine Acetate Presented at Ninth Eilat Conference on New Anti-Epileptic Drugs
Sepracor Completes Acquisition of Oryx Pharmaceuticals and Expands Operations in Canada
Sepracor Names Robert F. Scumaci as Chief Financial Officer - May 27 2008 12:53AM
David P. Southwell to Resign as Chief Financial Officer of Sepracor - May 27 2008 12:53AM
LUNESTA(R) Study of Patients with Insomnia and Co-Morbid Generalized Anxiety Disorder (GAD) Published in Archives of General Psychiatry - Jun 2 2008 3:53AM
BellwetherReport.com Initiates Analyst Coverage on SEPR, CNQR, ICON, and VLCM - May 27 2008 1:16AM
Sepracor Inc. Reports First Quarter 2008 Results, Certain Strategic Initiatives and Settlement of XOPENEX(R) Patent Litigation with Breath Limited - Jun 2 2008 3:53AM
Sepracor to Acquire Oryx Pharmaceuticals Inc. and Expand Commercial Operations into Canada - Jun 2 2008 3:53AM
Sepracor and Arrow Sign Global License and Development Agreement for XOPENEX(R)/Ipratropium Inhalation Solution Combination - Jun 2 2008 3:53AM
Sepracor Announces Final Settlement of XOPENEX(R) Inhalation Solution Patent Infringement Litigation with Breath Limited - Jun 2 2008 3:53AM
Sepracor and Arrow Sign Global License and Development Agreement Covering Technology to Enhance Ciclesonide and BROVANA(R) Franchises - Jun 2 2008 3:53AM
HeartWare Appoints Timothy J. Barberich to Board of Directors
Sepracor Inc. Sets Conference Call and Webcast for First Quarter Operating Results
Sepracor Launches ''My Allergies in America'' Web Site, a New Online Resource for Physicians and Nasal Allergy Sufferers
OMNARIS(TM) Nasal Spray Now Available by Prescription for Patients with Seasonal and Perennial Allergies
QED International Associates Announces Changes to the HealthShares(TM) Respiratory Pulmonary Index and the HealthShares(TM) Composite Index
Seven Summits Research Releases Comments on GOOG, ERTS, CAL, SEPR, and ICE
Shuman & Berens LLP Encourages Persons Who Currently Own Sepracor Inc. Common Stock to Consider Their Legal Options Concerning Stock Option Backdating at the Company
(OTC PK: ECFL) eCarfly Discusses 10-1 Forward Stock Split
SmallCap Sentinel: The Ever-Increasing Applications for Non-Controversial Adult Stem Cells
Seven Summits Research Releases Alerts on INTC, CSCO, BA, PEP, and SEPR